Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$41.97 USD
-1.12 (-2.60%)
Updated May 3, 2024 04:00 PM ET
After-Market: $41.93 -0.04 (-0.10%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Ionis Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2,331 | 1,987 | 2,115 | 1,892 | 2,500 |
Receivables | 98 | 26 | 62 | 76 | 63 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 28 | 22 | 25 | 22 | 18 |
Other Current Assets | 184 | 168 | 143 | 140 | 140 |
Total Current Assets | 2,642 | 2,203 | 2,345 | 2,131 | 2,721 |
Net Property & Equipment | 71 | 74 | 178 | 181 | 154 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 306 |
Intangibles | 0 | 0 | 29 | 28 | 26 |
Deposits & Other Assets | 105 | 75 | 60 | 50 | 28 |
Total Assets | 2,990 | 2,534 | 2,612 | 2,390 | 3,233 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 26 | 18 | 12 | 17 | 16 |
Current Portion Long-Term Debt | 44 | 0 | 4 | 300 | 2 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 216 | 189 | 127 | 156 | 104 |
Income Taxes Payable | 2 | 6 | 0 | 1 | 33 |
Other Current Liabilities | 160 | 98 | 98 | 108 | 118 |
Total Current Liabilities | 448 | 312 | 241 | 583 | 273 |
Mortgages | 0 | 9 | 60 | 60 | 60 |
Deferred Taxes/Income | 241 | 288 | 352 | 424 | 490 |
Convertible Debt | 1,188 | 1,167 | 1,161 | 456 | 710 |
Long-Term Debt | 42 | 7 | 26 | 23 | 16 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 514 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,603 | 1,961 | 1,840 | 1,546 | 1,549 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,215 | 2,060 | 1,964 | 2,114 | 2,204 |
Retained Earnings | -1,796 | -1,430 | -1,160 | -1,249 | -708 |
Other Equity | -33 | -57 | -33 | -21 | 188 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 387 | 573 | 772 | 843 | 1,685 |
Total Liabilities & Shareholder's Equity | 2,990 | 2,534 | 2,612 | 2,390 | 3,233 |
Total Common Equity | 387 | 573 | 772 | 843 | 1,685 |
Shares Outstanding | 143.40 | 142.00 | 141.20 | 139.80 | 140.60 |
Book Value Per Share | 2.70 | 4.03 | 5.47 | 6.03 | 11.98 |
Fiscal Year End for Ionis Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 2,331 | 2,236 | 2,385 | 2,347 |
Receivables | NA | 98 | 142 | 28 | 14 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 28 | 26 | 26 | 22 |
Other Current Assets | NA | 184 | 181 | 178 | 160 |
Total Current Assets | NA | 2,642 | 2,585 | 2,617 | 2,543 |
Net Property & Equipment | NA | 71 | 71 | 92 | 85 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 105 | 104 | 86 | 78 |
Total Assets | NA | 2,990 | 2,934 | 2,971 | 2,885 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 26 | 6 | 24 | 11 |
Current Portion Long-Term Debt | NA | 44 | 0 | 0 | 8 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 216 | 153 | 134 | 131 |
Income Taxes Payable | NA | 2 | 31 | 25 | 17 |
Other Current Liabilities | NA | 160 | 215 | 105 | 92 |
Total Current Liabilities | NA | 448 | 404 | 288 | 259 |
Mortgages | NA | 0 | 49 | 0 | 9 |
Deferred Taxes/Income | NA | 241 | 249 | 254 | 273 |
Convertible Debt | NA | 1,188 | 1,230 | 1,299 | 1,168 |
Long-Term Debt | NA | 42 | 0 | 16 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 513 | 510 | 513 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 2,603 | 2,619 | 2,543 | 2,399 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 2,215 | 2,148 | 2,118 | 2,089 |
Retained Earnings | NA | -1,796 | -1,787 | -1,639 | -1,554 |
Other Equity | NA | -33 | -46 | -51 | -49 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 387 | 315 | 428 | 487 |
Total Liabilities & Shareholder's Equity | NA | 2,990 | 2,934 | 2,971 | 2,885 |
Total Common Equity | 0 | 387 | 315 | 428 | 487 |
Shares Outstanding | 145.70 | 143.40 | 143.40 | 143.10 | 143.00 |
Book Value Per Share | 0.00 | 2.70 | 2.20 | 2.99 | 3.40 |